Parkinson's disease trials recruiting in New York

All Parkinson's disease trials nationally

Cities in New York

Recruiting trials in New York

• A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
  NCT06753331 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 72 Years · Sex: All (male and female) · New York: New York
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · New York: Manhasset, New York, Rochester
• A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
  NCT05539196 · Phase: Not specified · Ages: 30 Years to 99 Years · Sex: All (male and female) · New York: New York
• A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
  NCT04991831 · Phase: Not specified · Ages: 30 Years to 99 Years · Sex: All (male and female) · New York: New York
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female) · New York: New York
• A Study of Buntanetap in Participants With PD
  NCT07284784 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 85 Years · Sex: All (male and female) · New York: New York
• A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
  NCT06765668 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
  NCT06976268 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · New York: Albany, New York
• A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
  NCT07432958 · Phase: Phase 2 · Ages: 30 Years to 80 Years · Sex: All (male and female) · New York: New York
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
  NCT07174310 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New York: Amherst, Commack, New York
• A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
  NCT07804615 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: Amherst, New York, Patchogue
• A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
  NCT06944522 · Phase: Phase 3 · Ages: 45 Years to 75 Years · Sex: All (male and female) · New York: Buffalo, New York
• A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
  NCT07330258 · Phase: Not specified · Ages: 45 Years to 75 Years · Sex: All (male and female) · New York: New York, Stony Brook, Williamsville
• Autoimmune Features of Neurodegenerative Disorders
  NCT04239079 · Phase: Not specified · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: New York
• Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients
  NCT05884944 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Old Westbury
• Effects of Osteopathic Manipulative Treatment Protocol on Sleep Quality in Parkinson's Disease Subjects
  NCT06671600 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · New York: Old Westbury
• Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
  NCT07207122 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 80 Years · Sex: All (male and female) · New York: New York
• GBPDC: Gut-Brain in PD Consortium Master Protocol
  NCT07567794 · Phase: Not specified · Ages: 21 Years to 80 Years · Sex: All (male and female) · New York: New York
• Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
  NCT07005180 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · New York: New York
• NYSCF Scientific Discovery Biobank
  NCT06203106 · Phase: Not specified · Ages: 30 Days and older · Sex: All (male and female) · New York: New York
• Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
  NCT06540989 · Phase: Early Phase 1 · Ages: 50 Years to 80 Years · Sex: All (male and female) · New York: New York
• Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients
  NCT06975059 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
  NCT04477785 · Phase: Not specified · Ages: 30 Years and older · Sex: All (male and female) · New York: New York, Rochester
• Parkinson's Disease Biomarkers in Nerve Cells in the Gut
  NCT05347407 · Phase: Not specified · Ages: 45 Years to 75 Years · Sex: All (male and female) · New York: New York
• Parkinson's Foundation PD GENEration Genetic Registry
  NCT04994015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York, Rochester
• Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
  NCT04373317 · Phase: Phase 4 · Ages: 40 Years and older · Sex: All (male and female) · New York: Syracuse
• Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
  NCT07219927 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack
• Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
  NCT02071134 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany, Great Neck, Williamsville
• Rehabilitation of Airway Protection in Parkinson's Disease
  NCT05700825 · Phase: Phase 2 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New York: New York
• Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
  NCT06993142 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: All (male and female) · New York: Rochester
• Speech Learning and Speech Production in Parkinson's Disease
  NCT07403539 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years and older · Sex: All (male and female) · New York: Buffalo
• This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
  NCT07102342 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 75 Years · Sex: All (male and female) · New York: New York
• Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms
  NCT07752355 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York